Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Viking Therapeutics, Inc.NASDAQ: VKTX
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $157K rose 40.2% year over year, ahead of the +7.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 84.7% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.2% holds above the trailing-twelve-month pace of +7.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 431K USD
- Year-over-year change
- +24.6%
- 4-year CAGR
- +9.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 431K | +24.6% |
| FY2024 | 2024-12-31 | 346K | +18.5% |
| FY2023 | 2023-12-31 | 292K | +0.3% |
| FY2022 | 2022-12-31 | 291K | -1.7% |
| FY2021 | 2021-12-31 | 296K | — |
Depreciation & Amortization vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 depreciation & amortization of $450K is the 3rd largest of the 7 companies compared; the peer median is $326.5K.
- Its year-over-year change of +7.1% is the 3rd highest of 6, against a peer median of +7.1%.
- Over three fiscal years its annual growth of +14.0% compares with a peer median of +47.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | LTM Sep 2026 | $1.64M | +3.3% | +40.6% | 1.7% |
| LTM Jun 2026 | $1.52M | +7.1% | +47.7% | 0.1% | |
| LTM Jun 2026 | $450K | +7.1% | +14.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K | +39.4% | +64.2% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $310K | — | — | — |
| LTM Jun 2026 | $244K | +38.6% | +190.2% | 3.4% | |
| LTM Mar 2026 | $8K | -89.5% | -44.2% | 0.0% | |
| Peer median (excluding VKTX) | $326.5K | +7.1% | +47.7% | 0.9% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M |
| Change in Working Capital | (2.93M) | 10.19M | 3.55M | 9.36M | 48.98M |
| Accounts Receivables | 1.18M | 614K | 321K | 1.2M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.54M) | 7.09M | (1.02M) | 2.3M | 43.44M |
| Other Working Capital | (1.56M) | 2.49M | 4.25M | 5.86M | 464K |
| Other Non-Cash Items | 3.94M | 1.32M | (8.07M) | (17.25M) | (9.27M) |
| Operating Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (168.02M) | (121.43M) | (478.3M) | (1.11B) | (418.04M) |
| Sales of Investments | 205.98M | 176.18M | 299.22M | 560M | 759.43M |
| Other Investing Activities | 0 | 54.75K | 0 | 0 | 0 |
| Investing Cash Flow | 37.96M | 54.75M | (179.09M) | (553.37M) | 341.39M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 7.59M | 0 | 269.76M | 597.09M | 2.49M |
| Common Stock Repurchased | 0 | (6.8M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (707K) | 12.49M | 1.62M | 15.37M | 73.95M |
| Financing Cash Flow | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M |
| Effect of Forex Changes | 0 | (258K) | (30K) | (148K) | (8K) |
| Net Change in Cash | (2.75M) | 10.26M | 18.88M | (28.84M) | 139.13M |
| Free Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.